Short Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Declines By 40.0%

Genenta Science S.p.A. (NASDAQ:GNTA) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 1,500 shares, a decrease of 40.0% from the February 13th total of 2,500 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 10,400 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC acquired a new position in Genenta Science S.p.A. (NASDAQ:GNTA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,167 shares of the company’s stock, valued at approximately $46,000. Citadel Advisors LLC owned 0.06% of Genenta Science as of its most recent SEC filing. Institutional investors and hedge funds own 15.13% of the company’s stock.

Genenta Science Stock Performance

GNTA stock traded down $0.11 during trading on Friday, hitting $3.84. The company had a trading volume of 1,273 shares, compared to its average volume of 8,263. The business has a 50 day moving average of $4.07 and a 200 day moving average of $4.54. Genenta Science has a fifty-two week low of $2.20 and a fifty-two week high of $7.28.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.